BC PharmaCare: Your Voice



Get Involved

or

Read the Ongoing Results of this Engagement

What is this engagement about?

The Ministry of Health has two main goals for the BC PharmaCare program:

  • To cover drugs that support the health and well-being of British Columbians; and
  • To make sure that the drugs PharmaCare covers are affordable and give the best value for money.

To meet the first goal, PharmaCare covers a drug only if it has a proven record of safety and effectiveness. To meet the second goal, PharmaCare compares each drug to the drugs it already covers that treat the same condition. For example, if more than one drug provides the same health benefit, PharmaCare may cover only the drug(s) that offers the best value.

Before PharmaCare decides if it will cover a drug, the drug goes through a full review to find out if covering it aligns with the goals above. Patients, caregivers and patient groups have the opportunity to add their voices to the drug review process.

The Ministry of Health is considering the following drugs for PharmaCare Coverage:

Generic name: estradiol and progesterone
Brand name: Bijuva®
Drug used for: Vasomotor symptoms associated with menopause
Input accepted: From Monday, October 25, 2021 to Monday, November 24, 2021 AT MIDNIGHT

Generic name: estradiol
Brand name: Imvexxy®
Drug used for: Postmenopausal dyspareunia (genital pain associated with sexual intercourse), caused by vulvar and vaginal atrophy (VVA)
Input accepted: From Monday, October 25, 2021 to Monday, November 24, 2021 AT MIDNIGHT

Generic name: mecasermin
Brand name: Increlex®
Drug used for: Severe primary insulin-like growth factor-1 deficiency (SPIGFD)
Input accepted: From Monday October 25, 2021 to Monday, November 24, 2021 AT MIDNIGHT AT MIDNIGHT

Generic name: trientine hydrochloride
Brand name: Waymade-Trientine
Drug used for: Wilson’s Disease
Input accepted: From Wednesday, November 17, 2021 to Wednesday, December 15, 2021 AT MIDNIGHT

Generic name: ravulizumab
Brand name: Ultomiris
Drug used for: Paroxysmal nocturnal hemoglobinuria
Input accepted: From Wednesday, November 17, 2021 to Wednesday, December 15, 2021 AT MIDNIGHT

Generic name: fostamatinib
Brand name: Tavalisse
Drug used for: Chronic immune thrombocytopenia
Input accepted: From Wednesday, November 17, 2021 to Wednesday, December 15, 2021 AT MIDNIGHT

Generic name: Biosynthetic human insulin
Brand name: Entuzity KwikPen
Drug used for: Diabetes mellitus
Input accepted: From Wednesday, November 17, 2021 to Wednesday, December 15, 2021 AT MIDNIGHT

To provide input, please visit our website.

How can my contribution make a difference?

All responses that are submitted during the open consultation are sent to the Drug Benefit Council. The Council takes the public’s input into consideration when they make their drug coverage recommendations. Drugs are posted for review on an ongoing basis.

Details of the Engagement:
Date: June 6, 2017
Status: Ongoing
Location: Province-wide
Category: Health & Safety
Types: Online

Get Involved

or

Read the Ongoing Results of this Engagement